Updates from American Society of Clinical Oncology (ASCO) - Quality
Originally presented November 15, 2018
Credits: 1 hour BCOP and/or 1 hour ACPE
BCOP credits are available to earn until March 26, 2019
Individual webinar pricing: $40 (member) / $70 (non-member)
This product is no longer available for purchase.
HOPA is pleased to present the fifth of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.
This webinar will highlight strategies and methods for improving the measurement and implementation of quality and safety in cancer care from the ASCO Quality Care Symposium 2018. Selected abstracts will feature promotes innovation, collaboration, and cooperation in cancer-focused quality measurement and improvement, and health services research.
Upon completion, attendees will be able to:
- Present significant research findings of key abstracts expected to impact patient-centered care and quality interventions related to: equity, value and policy.
- Demonstrate challenges of financial toxicity in cancer care and highlight opportunities to mitigate.
- Illustrate innovations and technology in care delivery by reviewing abstracts to improve: patient experience and safety.
Brandy Strickland Snyder, PharmD BCOP CPP
Dr. Brandy Strickland Snyder, PharmD BCOP CPP, is the Assistant Director of Hematology/Oncology & Investigational Drug Services at Wake Forest Baptist Health in Winston-Salem, NC. She is currently enrolled at New England College and will be obtaining her Master's in Business Administration with a concentration in Health Care Management in December 2018. She also received her B.S. Biological Sciences from N.C. State University and earned her doctorate in pharmacy from the University of N.C. at Chapel Hill, Eshelman School of Pharmacy. She completed her PGY1 and PGY2 oncology residency training at Moses Cone Health in Greensboro, NC. Following residency, she joined Wake Forest and developed the pediatric oncology clinical specialist role before becoming the Systems Manager for Oncology for several years. In this position she also completed the ASHP, Pharmacy Leadership Academy.
Dr. Snyder is a preceptor for students and residents and is actively involved in several institutional committees and working groups. She is active in HOPA and has served in various committees over the last 10 years. She is currently serving on the HOPA Practice Management Committee and Vizient Cancer Care Committee for 2018-2019.
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-077-H04-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by May 14, 2019.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.